Published in Postepy Dermatol Alergol on February 25, 2014
Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies. Postepy Dermatol Alergol (2014) 0.75
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med (2016) 0.75
Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report. Postepy Dermatol Alergol (2014) 0.75
Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia. Postepy Dermatol Alergol (2015) 0.75
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med (2013) 7.34
Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev (2006) 2.47
Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges (2013) 2.33
Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy (2007) 2.22
Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest (2010) 1.95
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol (2013) 1.91
After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy (2009) 1.74
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol (2011) 1.64
The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir Med (2013) 1.27
Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol (2009) 1.13
Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol (2012) 1.03
Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med (2012) 1.01
Loss of asthma control after cessation of omalizumab treatment: real life data. Postepy Dermatol Alergol (2014) 1.01
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med (2014) 0.99
The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy (2010) 0.97
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol (2011) 0.96
Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust. Postepy Dermatol Alergol (2014) 0.93
Anti-IgE--emerging opportunities for Omalizumab. Expert Opin Biol Ther (2013) 0.92
Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol (2013) 0.90
Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol (2012) 0.89